These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31695028)

  • 1. An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence.
    Lee CH; Kang TH; Godon O; Watanabe M; Delidakis G; Gillis CM; Sterlin D; Hardy D; Cogné M; Macdonald LE; Murphy AJ; Tu N; Lee J; McDaniel JR; Makowski E; Tessier PM; Meyer AS; Bruhns P; Georgiou G
    Nat Commun; 2019 Nov; 10(1):5031. PubMed ID: 31695028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
    Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
    MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors.
    Goulet DR; Zwolak A; Williams JA; Chiu ML; Atkins WM
    Proteins; 2020 May; 88(5):689-697. PubMed ID: 31702857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
    Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
    MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.
    Yuan D; Rode F; Cao Y
    AAPS J; 2018 Mar; 20(3):48. PubMed ID: 29541870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life.
    Andersen JT; Foss S; Kenanova VE; Olafsen T; Leikfoss IS; Roopenian DC; Wu AM; Sandlie I
    J Biol Chem; 2012 Jun; 287(27):22927-37. PubMed ID: 22570488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
    Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
    Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.
    Schlothauer T; Rueger P; Stracke JO; Hertenberger H; Fingas F; Kling L; Emrich T; Drabner G; Seeber S; Auer J; Koch S; Papadimitriou A
    MAbs; 2013; 5(4):576-86. PubMed ID: 23765230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
    Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
    Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
    Proetzel G; Roopenian DC
    Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
    Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
    Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies.
    Roopenian DC; Christianson GJ; Sproule TJ
    Methods Mol Biol; 2010; 602():93-104. PubMed ID: 20012394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.
    Wilkinson IC; Fowler SB; Machiesky L; Miller K; Hayes DB; Adib M; Her C; Borrok MJ; Tsui P; Burrell M; Corkill DJ; Witt S; Lowe DC; Webster CI
    MAbs; 2013; 5(3):406-17. PubMed ID: 23567207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human
    Low BE; Christianson GJ; Lowell E; Qin W; Wiles MV
    MAbs; 2020; 12(1):1829334. PubMed ID: 33025844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies.
    Ko S; Park S; Sohn MH; Jo M; Ko BJ; Na JH; Yoo H; Jeong AL; Ha K; Woo JR; Lim C; Shin JH; Lee D; Choi SY; Jung ST
    Exp Mol Med; 2022 Nov; 54(11):1850-1861. PubMed ID: 36319752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc engineered anti-virus therapeutic human IgG
    Park SA; Lee Y; Hwang H; Lee JH; Kang YJ; Kim Y; Jin C; An HJ; Oh YJ; Hinterdorfer P; Kim E; Choi S; Ko K
    Biotechnol J; 2024 Mar; 19(3):e2300552. PubMed ID: 38528347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments.
    Mi W; Wanjie S; Lo ST; Gan Z; Pickl-Herk B; Ober RJ; Ward ES
    J Immunol; 2008 Dec; 181(11):7550-61. PubMed ID: 19017944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An engineered human IgG1 antibody with longer serum half-life.
    Hinton PR; Xiong JM; Johlfs MG; Tang MT; Keller S; Tsurushita N
    J Immunol; 2006 Jan; 176(1):346-56. PubMed ID: 16365427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.